TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-3.30%+2.97%+54.99%+104.15% 74.18B
-0.12%-1.63%+33.14%+74.86% 59.55B
+2.71%-1.96%-13.79%+371.49% 25.84B
+0.81%+0.61%-0.49%-3.74% 24.73B
-1.05%+2.58%+24.27%-10.32% 20.87B
-1.70%-4.15%+147.82%+325.69% 15.32B
+2.15%-0.92%+48.93%+165.46% 14.06B
-0.43%-7.56%-20.10%+753.12% 13.12B
+0.04%-3.97%+20.23%+240.01% 11.85B
Average -0.09%-0.80%+32.78%+224.52% 28.84B
Weighted average by Cap. -0.71%-0.22%+35.14%+159.98%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock